A rapid overview of three of these treatments: ablation, chemoembolization and selective interval radiation therapy, should help clarify the challenges and difficulties of determining tumour response in interventional oncology, write Maxime Ronot and Valérie Vilgrain.
Hansen has announced the completion of the world’s first clinical procedure with the Magellan 10F robotic catheter. Interventional radiologist Gerard Goh performed the procedure at The Alfred Hospital in Melbourne, Australia. He used the 10F catheter during a robot-assisted placement of an inferior vena cava filter.
Lombard Medical has announced the enrolment and treatment of the first patient in the ARCHYTAS global registry. An 89-year-old male with a 64mm aneurysm and challenging 75-degree aortic neck angulation was treated with Lombard Medical’s Aorfix endovascular stent graft in Girona, Spain.
EndoShape has announced that it has been selected to present at the Cavendish Global Health Impact Forum taking place 10–14 May in La Jolla, USA.
Quiremspheres, that were developed by the University Medical Center (UMC) Utrecht, The Netherlands, to be used in a new treatment for liver cancer, have received the European CE mark for quality and safety. The treatment is being marketed by Quirem Medical, a spin-off company of the UMC Utrecht.
Surefire Medical has announced that the company’s new Precision targeted delivery infusion system, for direct-to-tumour embolization procedures, has received the CE mark from European regulators. Surefire infusion systems are today used primarily in treating inoperable liver cancers, although clinical trials are under way for additional medical conditions.
VesselNavigator has been designed for use in conjunction with Philips’ interventional X-ray systems to guide catheters during treatment of vascular disease. The new system allows for a major reduction of contrast medium (70%) demonstrated in clinical study, enabling minimally invasive treatment of aortic aneurysms in a number of patients who are currently unable to benefit from minimally-invasive techniques.
Micro-mesh stents and sustained anti-embolic action to reduce cerebral embolisation may contribute to solving the remaining limitations of carotid stenting, according to Alberto Cremonesi (Cotignola, Italy), who spoke at CX 2015 (28 April–1 May, London, UK).
A clinical trial evaluating Eluvia Drug-Eluting Vascular Stent System (Boston Scientific) has met its primary endpoint with more than 94% of the lesions treated remaining open at nine months post implantation. This was accompanied by a target lesion revascularisation rate of less than 4%.
Results from the 12-month data of the randomised controlled IMPROVE trial, presented for the first time at CX 2015 (28 April–1May, London, UK), show that an endovascular strategy is cost-effective when compared to open repair in the treatment of ruptured abdominal aortic aneurysms. The one-year data also revealed that the endovascular strategy conferred no survival benefit over open repair, except a trend towards benefitting women. It also showed that the endovascular strategy enabled more patients to be discharged from hospital to home, and significantly faster than with open repair. Patients also have an excellent quality of life with endovascular strategy, if they survive the rupture, delegates heard.
Drug-coated balloon technology is unlikely to be a successful “stand alone” treatment for the majority of medium and long length superficial femoral artery lesions, the voting results from CX2015 implied. The voting showed that the audience felt that drug-coated balloon use was best suited to short lesions. The randomised controlled trial data for drug-coated balloons are mostly based on short lesions and 57% of the audience voted “no” to the question, “Is drug-eluting balloon technology likely to be a successful standalone treatment for the majority of medium and long length superficial femoral artery lesions?” The session in which the vote was held was titled “Leaving nothing behind” and also saw the presentation of the ILLUMENATE first-in-human study 24-month results. These were favourable for the Stellarex drug-coated balloon (Spectranetics), and came close on the heels of updates on the Lutonix drug-coated balloon (Bard) and the IN.PACT Admiral drug-coated balloon (Medtronic). Atherectomy as a pretreatment also received a boost.
Yasuaki Arai, director of the National Cancer Center Hospital, Tokyo, Japan, and current president of the Japanese Society of Interventional Radiology (JSIR), delivered the Honorary Lecture at the European Conference of Interventional Oncology (ECIO) in Nice, France, yesterday. He spoke on the topic “Beyond the evidence—the true goal of interventional oncology” and received a standing ovation for his presentation.
Essential Medical has successfully completed additional clinical studies using its Manta 14F large bore vascular closure device, a vascular closure device designed to seal both 14F and 18F large bore femoral punctures.
The CX Imaging Day provided a comprehensive programme of state-of-the-art imaging that is applied to the aorta, carotid, peripheral arteries and veins, including planning and using hybrid theatres, robotics, 3D fusion and guidance, intravascular ultrasound, perfusion angiography, cone beam computed tomography and carbon dioxide angiography.
Michael Dake, Stanford, USA, presented the initial results with the GORE TAG Thoracic Branch Endoprosthesis (TBE), a new device for treatment of the aortic arch at CX yesterday.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos